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1098Objective: This study assesses in a baboon model the hemodynamics and human leukocyte antigen immuno-
genicity of chronically implanted bioengineered (decellularized with collagen conditioning treatments) human
and baboon heart valve scaffolds.
Methods: Fourteen baboons underwent pulmonary valve replacement, 8 with decellularized and conditioned
(bioengineered) pulmonary valves derived from allogeneic (N ¼ 3) or xenogeneic (human) (N ¼ 5) hearts;
for comparison, 6 baboons received clinically relevant reference cryopreserved or porcine valved conduits.
Panel-reactive serum antibodies (human leukocyte antigen class I and II), complement fixing antibodies (C1q
binding), and C-reactive protein titers were measured serially until elective sacrifice at 10 or 26 weeks. Serial
transesophageal echocardiogramsmeasured valve function and geometry. Differences were analyzed with Krus-
kal–Wallis and Wilcoxon rank-sum tests.
Results: All animals survived and thrived, exhibiting excellent immediate implanted valve function by transe-
sophageal echocardiograms. Over time, reference valves developed a smaller effective orifice area index (me-
dian, 0.84 cm2/m2; range, 1.22 cm2/m2), whereas all bioengineered valves remained normal (effective orifice
area index median, 2.45 cm2/m2; range, 1.35 cm2/m2; P ¼ .005). None of the bioengineered valves developed
elevated peak transvalvular gradients: 5.5 (6.0) mm Hg versus 12.5 (23.0) mm Hg (P ¼ .003). Cryopreserved
valves provoked the most intense antibody responses. Two of 5 human bioengineered and 2 of 3 baboon bioen-
gineered valves did not provoke any class I antibodies. Bioengineered human (but not baboon) scaffolds pro-
voked class II antibodies. C1qþ antibodies developed in 4 recipients.
Conclusions:Valve dysfunction correlated with markers for more intense inflammatory provocation. The tested
bioengineering methods reduced antigenicity of both human and baboon valves. Bioengineered replacement
valves from both species were hemodynamically equivalent to native valves. (J Thorac Cardiovasc Surg
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The Journal of Thoracic and Cardiovascular SurThere is increasing interest in subhuman primates for bio-
medical research.1 However, they are rarely used for evalu-
ating bioengineered cardiovascular constructs. The genus
Papio (baboons) is potentially valuable for comparative
tissue-engineering research given significant similarities
with humans in cardiac anatomy, physiology, valve dimen-
sions, resident antigens, and innate and acquired immune
systems. Yet there are few reported baboon chronic survival
cardiac surgical replacement valve performance studies.2,3
A baboon orthotopic valve replacement model could be
a significant preclinical tool for bridging cardiovascular
tissue engineering to ‘‘real world’’ clinical applications.
Papio hamadryas Anubis, an Old World monkey species,
is genetically more similar to Homo sapiens compared
with other nonhominoid primates and far more so than
hoofed food stock ungulate mammals (Figure E1). The lat-
ter are often used both as valve test models (eg, sheep) and
as source material (eg, porcine) for bioprosthetic valves. In-
ternational standards and regulatory guidelines for implant-
able cardiovascular devices typically require large animal
preclinical in vivo validation studies.4 For evaluatinggery c April 2013
Abbreviations and Acronyms
EOA ¼ effective orifice area
H&E ¼ hematoxylin and eosin
HLA ¼ human leukocyte antigen
PRA ¼ panel-reactive antibody
TEE ¼ transesophageal echocardiogram
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is typically chosen because it is robust and sensitive for
predicting valve structural failure due to dystrophic calcifi-
cation.5 However, all ungulates express powerful non–
human leukocyte antigen (HLA) xeno-epitopes, such as
alpha-galactosyl, to which all catarrhines (humans, apes,
and Old World Monkeys) possess natural antibodies.
Conversely, ungulates cannot be used to directly test
human-derived uncrosslinked tissue because of profound
xenotransplant rejection.6 After removal of cells, it is not
known whether heart valve extracellular matrix scaffolds
remain functionally antigenic and proinflammatory across
catarrhine species. Thus, for both mechanistic research
and possible regulatory utility, these studies were under-
taken to evaluate the suitability of the baboon as a subhuman
primate model for testing clinical prototype bioengineered
heart valves.
The current clinical standard for pediatric valved conduit
reconstructions is the cryopreserved, cadaver-derived allo-
graft ‘‘biologic’’ pulmonary valve, historically termed valve
‘‘homografts.’’ As traditionally prepared, donor cells are re-
tained through surgical implantation, yet these valves do
not grow, and the donor cell population disappears; durabil-
ity is limited especially in infants and children, typically fail-
ing because of dystrophic calcification driven by chronic
inflammation.7 Cryopreserved human homografts have
been conclusively shown to contain HLA antigens capable
of provoking antibodies in recipients.8 To reduce inflamma-
tory responses, various tissue decellularization treatments of
allogeneic tissues have been devised, and some show
promise.9-11 Unlike allografts, the clinical results with
decellularized porcine valve xenografts have been poor
with accelerated inflammatory destruction.12,13 This
research uses valve scaffolds bioengineered (decellularized
and conditioned) and designed to be optimal, minimally
proinflammatory, and attractive biologically to cells
in vitro and in vivo.14,15 As tested in the current study,
these are not tissue-engineered heart valves. Tissue-
engineered heart valves are a subset of bioengineered in
which the scaffolds are seeded with cells in a bioreactor be-
fore implantation. The bioengineered valve scaffolds tested
in these studies are acellular but otherwise inherently similar
to native valves in design, hemodynamic performance, ma-
trix chemistry, and material properties.10,16,17 As such, they
could function as the platform or scaffold for a tissue-The Journal of Thoracic and Carengineered valve, and because a scaffold without cells at
the time of surgical implantation is the ‘‘worst case’’ scenario
for a tissue-engineered construct in which seeded cells have
failed to repopulate, it is the appropriate starting point for the
development of new evaluative tools for preclinical assess-
ment of tissue-engineered heart valves.MATERIALS AND METHODS
Donors, Recipients, and Surgery
Fourteen healthy postpubescent male baboons weighing 28 to 34 kg
were selected as recipients. Donors were unrelated animals 2 to 4 kg larger
than the recipients. Anesthesia and cardiopulmonary bypass methods were
refined as previously reported by us.18 All recipients had excision of native
valves and main pulmonary artery segments, and then test valve conduits
were inserted with standard homograft surgical techniques using end-
to-end anastomoses. Five were replaced with human bioengineered pulmo-
nary valves for 10 weeks (N ¼ 3) or 26 weeks (N ¼ 2); 3 received
bioengineered baboon pulmonary valves for a duration of 10 weeks. Three
types of clinically analogous alternatives (N ¼ 6) were used as reference
valves: cryopreserved pulmonary valves from humans (N ¼ 2), baboons
(N ¼ 2), and stentless porcine (N ¼ 2) bioprostheses (size 21 Medtronic
Freestyle, Medtronic, Inc, Minneapolis, Minn). Studies were performed
with Institutional Animal Care and Use Committee approval (Southwest
National Primate Research Center), in accordance with the Guide for the
Care and Use of Laboratory Animals (National Research Council, 2011).
Preparation of Bioengineered Valves
Baboon pulmonary valves were harvested and cryopreserved with clin-
ical methods.7 Seven cryopreserved humanvalves at the end of storage time
limits were obtained from a clinical tissue bank (LifeNet Health, Virginia
Beach,Va).Human and baboonbioengineered valveswere prepared by sub-
sequent decellularization using a previously reported laboratory developed,
double-solvent, multidetergent, enzyme-assisted, reciprocating osmotic
cell fracture method optimized for pulmonary valves.10 Before implanta-
tion, all decellularized valves were conditioned in solutions designed to
acidify tissue pH, rehydrate the collagen helix moisture envelope, align
and compact collagen fibrils, and restore soluble proteins to the matrix.16
These decellularized-conditioned valves are termed ‘‘bioengineered.’’
Transesophageal and Dobutamine Stress
Echocardiography
Valve performance was evaluated by transesophageal echocardiogram
(TEE) and dobutamine stress echocardiography with geometric dimen-
sions and functional parameters measured and calculated as recommended
for evaluation of prosthetic heart valves by the American Society of Echo-
cardiography.19 A 5.0/3.7 MHz omni-plane TEE probe (Philips Medical
Systems, Andover, Mass) was positioned after induction of general anes-
thesia. Images were captured in real time on an HP SONOS 2500 platform
(Philips Medical Systems) and recorded for quantitative offline analyses.
Baseline measurements were performed before cardiopulmonary bypass
and after sternotomy closure during stable hemodynamics. Dobutamine
was administered intravenously as a continuous infusion (Sigma Spectrum
Volumetric Infusion pump; Sigma International, Inc, Medina, NY), with
measurements repeated at dosages of 2 and 4 mg/kg/min. Terminal mea-
surements were similarly performed. Leaflet thicknesses were measured
in triplicate by 2-dimensional and M-mode echocardiography.
Serial Panel-Reactive Antibodies, Complement
Fixation, C-Reactive Protein Titers
Immediate pre- and postoperative and serial weekly postoperative
serum samples were assayed qualitatively for the development ofdiovascular Surgery c Volume 145, Number 4 1099
TABLE 1. Echocardiography measurements of test and reference valves
Valve implant type Examination N
Valve diameter
(2D echocardiography)
cm
Maximum geometric
valve area*
cm2
Bioengineered valves
Papio Day 0 3 1.58 (0.29) 1.96 (0.75)
Bioengineered 10 wk 3 1.76 (0.19) 2.43 (0.50)
Human Day 0 5 2.11 (0.64) 3.50 (2.11)
Bioengineered 10 wk 5 2.00 (0.51) 3.14 (1.49)
26 wk 2 1.97 (0.13) 3.04 (0.40)
Reference valves
Papio Day 0 2 1.68 (0.15) 2.21 (0.39)
Cryopreserved 10 wk 2 1.52 (0.08) 1.82 (0.19)
Human Day 0 2 2.01 (0.18) 3.18 (0.57)
Cryopreserved 10 wk 2 1.75 (0.30) 2.42 (0.82)
Porcine Day 0 2 1.65 (0.40) 2.17 (1.04)
Glutaraldehyde 10 wk 2 1.97 (0.06) 3.05 (0.19)
All bioengineeredz 10 wk 8 1.76 (0.54) 2.43 (1.56)
All reference valvesz 10 wk 6 1.75 (0.52) 2.42 (1.42)
Data reported as median (range). Porcine glutaraldehyde, Papio cryopreserved, and human cryopreserved valves are reference valves, whereas Papio 10-week, human 10-week,
and human 6-month implant valves are bioengineered valves. 2D, 2-dimensional; EOA, effective orifice area; EOAI, effective orifice area index; BSA, body surface area.
*Maximum geometric test valve areas (theoretic) are calculated by measuring the internal annulus diameters at the time of implantation and explantation with Hegar dilators.
yBSA calculated by the Haycock formula. zAll bioengineered versus all reference valves at 10 weeks: xP ¼ .0003, kP ¼ .003, {P ¼ .005, #P ¼ .002.
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HLA bead assay (One Lambda, Inc, Canoga Park, Calif) run on a Luminex
200 System (Luminex, Inc, Austin, Tex) after serum purification (HiTrap;
Amersham Biosciences, Buckinghamshire, England). All sera were also
assayed with a second assay, LABScreen PRA (One Lambda, Inc), to con-
firm positivity and calculate the clinically familiar percentage PRA devel-
oping to class I and II antigens. This%PRA assay contains bead sites to 55
class I and 32 class II phenotypes and allows for some discrimination of re-
sponsible antigen specificities. Serum C-reactive protein titers were mea-
sured by enzyme-linked immunosorbent assay at day 0 and days 7, 35,
and 70 postoperatively (Monkey CRP; Life Diagnostics, West Chester,
Pa). Class I complement-fixing immunoglobulin-G antibodies were mea-
sured with a solid-state assay (C1q Screen, One Lambda, Inc).
Explant Pathology Methods
At necropsy, the heart lung block was removed and severity of pericar-
dial adhesions was scored (absent, mild, moderate, severe). Test valves
were excised with cuffs of native tissue beyond both anastomoses for ex-
plant pathology evaluations. Explanted valves were fixedwith HistoChoice
MB (Amresco, Solon, Ohio) and photographed without magnification
(Sony Cybershot, San Diego, Calif) and at macroscopic 6.33 (SteREO
Discovery V12; Carl Zeiss, Thornwood, NY) to document visual observa-
tions and imaged with radiographic methods for calciummineral formation
(Faxitron-LR, Lincolnshire, Ill). Longitudinal sections were cut through
each cusp, from the free edge to the base, including the corresponding sinus
and arterial wall. Paraffin-embedded sections were used for routine hema-
toxylin and eosin (H&E) stains (American Histo Laboratory, Gaithersburg,
Md). For immunohistochemistry, after antigen retrieval (10 minutes, 90C;
Antigen Unmasking Solution, Vector Laboratories, Burlingame, Calif) de-
paraffinized sections of each valve were incubated overnight with a 1:25
dilution of CD79 (B-cell; mouse monoclonal; Dako, Glostrup, Denmark)
followed by application of a secondary antibody (alkaline phosphatase-
conjugated; VECTASTAIN ABC-AP Kits, Vector Laboratories). Slides
were examined via light and fluorescence microscopy with digital camera
and imaging software (Axio Imager.Z1; Axio Vision, Carl Zeiss). Multiple1100 The Journal of Thoracic and Cardiovascular Surlow-magnification (2.53) H&E images from each entire valved conduit
were blindly reviewed (S.L.H.), and the inflammatory response was scored
on the basis of the maximum percentage of tissue area per low-power field
infiltrated with inflammatory cells: minimal (0%-10%), mild (10%-25%),
moderate (25%-50%), or marked (50%-100%).
Statistical Methods
Kolmogorov–Smirnov test for normality indicated these data sets were
not normally distributed, so nonparametric tests were used and values re-
ported as median (range). Differences between groups were analyzed for
continuous variables with the Kruskal–Wallis test and for ordinal variables
by the Wilcoxon rank-sum test. SAS 9.2 (SAS Institute, Inc, Cary, NC) and
SPSS version 17 (SPSS, Inc, Chicago, Ill) were used. Bonferroni correction
was applied for multiple comparisons.RESULTS
Clinical Outcomes
All baboons were successfully weaned from cardiopul-
monary bypass and survived and thrived. One recipient eas-
ily tolerated emergency open surgical removal of an
intercurrent gastric bezoar (hair).Two-Dimensional and Doppler Echocardiographic
Assessment of Valve Performance
Compared with bioengineered valves, reference valves
developed higher peak (20.0 [29.0] mm Hg vs 5.5 [6.0]
mm Hg, P ¼ .0003) and mean (12.5 [23.0] mm Hg vs
3.5 [4.0] mm Hg, P ¼ .003) pressure gradients by 10
weeks postimplant (Table 1). None of the bioengineered
valves developed elevated resting valve gradients
(Figure 1). The majority (5 of 6) of the reference valvesgery c April 2013
Peak gradient
(Doppler)
mm Hg
Mean gradient
(Doppler)
mm Hg
EOA
(Doppler)
cm2
EOAI to BSA
(Doppler)
cm2/m2
Cardiac output
mL/min
BSAy
m2
4.0 (6.0) 3.0 (4.0) 1.96 (0.93) 2.40 (0.93) 3251 (2994) 0.79 (0.16)
5.0 (3.0) 2.0 (2.0) 2.28 (0.92) 3.09 (1.03) 4143 (11) 0.76 (0.11)
3.0 (1.0) 2.0 (0.0) 2.05 (0.36) 2.65 (0.39) 3398 (1878) 0.78 (0.09)
8.0 (6.0) 3.0 (4.0) 1.73 (1.14) 2.32 (1.28) 4705 (3797) 0.78 (0.15)
4.0 (4.0) 2.0 (2.0) 2.5 (0.06) 3.15 (0.07) 3708 (1344) 0.80 (0.04)
6.0 (0.0) 3.5 (1.0) 2.12 (0.43) 2.64 (0.06) 5040 (2955) 0.80 (0.15)
23.0 (18.0) 14.5 (11.0) 0.68 (0.41) 0.84 (0.35) 2755 (2) 0.79 (0.16)
4.5 (1.0) 2.0 (0.0) 2.33 (0.47) 2.75 (0.17) 3980 (2379) 0.84 (0.14)
12.0 (8.0) 7.5 (5.0) 1.35 (0.41) 1.57 (0.43) 3940 (2179) 0.85 (0.03)
5.0 (4.0) 3.0 (2.0) 2.19 (1.15) 2.59 (1.34) 4270 (383) 0.84 (0.01)
35.5 (23.0) 21.5 (13.0) 0.52 (0.06) 0.61 (0.08) 2776 (825) 0.85 (0.01)
5.5 (6.0)x 3.5 (4.0)k 1.77 (1.19){ 2.45 (1.35)# 4148 (3797) 0.78 (0.16)
30.0 (39.0)x 12.5 (23.0)k 0.72 (1.08){ 0.84 (1.22)# 2813 (2666) 0.85 (0.16)
Table 1. Continued
Hopkins et al Evolving Technology/Basic Sciencedeveloped cusp thickening (1.5 mm) and restriction in
cusp excursion (Table 2). In contrast, mild cusp thickening
was seen in only 1 bioengineered valve (animal number
10), and all had normal cusp mobility. Bioengineered
valves maintained stable normal effective orifice areas
(EOAs) to 10 and 26 weeks. Reference valves developed
markedly decreased EOA compared with the bioengi-
neered valve group (0.72 [1.08] cm2 vs 1.77 [1.19] cm2,FIGURE 1. Dobutamine echocardiography results after chronic implantation o
process preparation for each group are noted. Porcine valves (light blue) were g
Inc, Minneapolis, Minn). Transvalvular gradients were uniformly lower for all bi
with the clinical reference valves (green) (A). The human bioengineered valves
imum dobutamine stimulation (B). *P  .005. PV, Pulmonary valve; BEV, bioe
The Journal of Thoracic and CarP ¼ .005). Bioengineered cusp dysfunctional regurgitation
was typically trace to mild, but was moderate for 1 C1qþ
recipient receiving a human-derived bioengineered valve
(animal number 10).
Dobutamine Stress Echocardiography
Dobutamine stress testing demonstrated marked differ-
ences in EOA and EOA index between reference andf human and baboon bioengineered and control valves. Source species and
lutaraldehyde crosslinked stentless valves (Medtronic Freestyle; Medtronic
oengineered valves (red) at rest and during dobutamine challenge compared
(orange) functionally had low gradients and normal indexed EOA at max-
ngineered valve; RVCO, right ventricular cardiac output.
diovascular Surgery c Volume 145, Number 4 1101
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TABLE 2. Serum human leukocyte antigen antibody serial assays and corresponding valve cusp function by transesophageal echocardiography
Valve type
No.
LABScreen mixed HLA assay* (One Lambda Inc, Canoga Park, Calif) LABScreen% PRA assayy
Class I Class II Class I Class II
Reference valves Result Time Result Time Result Time Result Time
Porcine 1 þ wk 3 – N/A 0% N/A 0% N/A
glutaraldehyde 2 – N/A þ wk 10 0% N/A 0% N/A
Papio cryopreserved 3 þþ wk 3 þþ wk 3 85% wk 3 98% wk 3
4 þ wk 10 þþ wk 4 95% wk 10 70% wk 6
Human cryopreserved 5 þþ wk 2 þþ wk 4 98% wk 2 98% wk 5
6 þ wk 4 þþ wk 3 60% wk 6 100% wk 4
Bioengineered valves
Papio 10-wk implant 7 – N/A – N/A – – – N/A
8 – N/A – N/A – N/A – N/A
9 þ wk 6 – N/A 65% wk 6 – N/A
Human 10-wk implant 10 þ wk 9 þþ wk 2 76% wk 9 100% wk 4
11 þ wk 1 þ wk 8 96% wk 1 14% wk 8
12 þ wk 6 þ wk 5 75% wk 6 20% wk 5
Human 6-mo implant 13 – N/A þ wk 6 0% N/A 100% wk 7
14 – N/A þ wk 9 0% N/A 100% wk 9
Porcine glutaraldehyde, Papio cryopreserved, and human cryopreserved valves are reference valves, whereas Papio 10-week, human 10-week, and human 6-month implant valves
decellularized and conditioned are termed ‘‘bioengineered valves.’’HLA,Human leukocyte antigen;PRA, panel-reactive antibody;N/A, not available. *Results of the LABScreen
mixed assay are scored as positive (þ; median fluorescence intensity>1000 units) or strongly positive (þþ; peak median fluorescence intensity>7000 units) for the postoperative
week at which the serum first measured as antibody positive. yResults of the LABScreen% PRA assay are reported as the maximum PRA titer (%) for the postoperative week
after the% PRA first exceeded 10%. Time points where the% PRAs were negative for the study duration are reported as N/A. zResults are the likely antigens responsible for
HLA-I or II sensitization as identified by reporting bead epitope sites. Epitopes can be shared by multiple antigens, so antibody specificities can arise against HLA antigens other
than those actually provoking the response. xHighly reactive indicates an inability to assign specificities due to intense reactivity. kCusps were designated as thickened when the
thickness measured by TEE was 1.5 mm; mildly thickened¼ cusp thickness 1.2 mm. Cusp regurgitation scores represent function at pre-death examination: trace (1þ), mild
(2þ), and moderate (3þ).19 {There was complete agreement on the measurement of cusp thickness by TEE and explant qualitative observations except for animal number 3
(compare with Table E1).
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valvular pressure gradients were consistently lower for
all bioengineered valves. At maximum dobutamine stimu-
lation, the reference valves had peak and mean pressure
gradients of 44.5 (76.0) mm Hg and 29.5 (49.0) mm
Hg, respectively. In contrast, the human bioengineered
valves had functionally low valve gradients (peak, 12.0
[12.0] mm Hg; mean, 7.0 [8.0] mm Hg) despite cardiac
indexes of 5 L/min/m2 or greater at the maximum dobut-
amine stimulation (P  .005 for all comparisons). For all
bioengineered valves, transvalvular gradients during stress
echocardiography were comparable to those across native
valves in each animal, suggesting the bioengineered
valves were functionally equivalent to native valves. The
geometric valve annulus diameters (Table 1) by direct
TEE measurement after 10 weeks for bioengineered
(1.76 [0.54] cm) and reference (1.75 [0.52] cm) valves
were the same (P> .05). Thus, the reductions in EOA
measured in reference valves were likely not due to ana-
tomic shrinkage but rather to increasing cuspal stiffness,
restricted cusp opening, and loss of conduit wall
compliance.1102 The Journal of Thoracic and Cardiovascular SurMixed Class I and II Human Leukocyte Antibodies
Screening Assay
The mixed screening assay accurately predicted whether
class I or II PRA titers would exceed 10% when measured
by quantitative LABScreen PRA % assay (Table 2). Both
allogeneic and xenogeneic cryo reference valves provoked
class I and II antibodies, typically as ‘‘strongly positive,’’
beginning relatively early (weeks 1-6) after implantation.
In contrast, 2 of 5 human and 2 of 3 baboon bioengineered
valves did not provoke class I antibodies. None of the bio-
engineered baboon valves provoked class II antibodies,
whereas all human tissues did.
Class I and Class II% Panel-Reactive Antibody
Assay
All cryopreserved donor valves provoked class I and II ti-
ters exceeding 60% by week 10 (Table 2) regardless of spe-
cies of origin. Baboon bioengineered valves were negative
for both class I and II elevations except for 1 animal (number
9) that developed 75% class I (and C1qþ) by week 6, but
which declined by week 10% to 47%. Two human bioengi-
neered valves remained class I negative (<10%) to 6months,gery c April 2013
Candidate HLA culprit specificitiesz,x
C1q
complement
Echocardiography (cusp)k,{
Class I Class II Thickness Mobility Regurgitation
None None – Thick Restricted 0
None None – Thick Restricted 1þ
A32, A29, A74, B18, B42, B27, B37, B38, B39, B47, B57 DQ7, DQ8, DR11, DR13, DR14 – Thick Restricted 0
A1, A10, A23, A24, A25, A3, A32, B48, B13, B62, B44,
B45, B60
DR1, DR10, D9, DR4, DQ7,
DQ5, DQ8, DQ9
þ (62%) Thick Restricted 2þ
Highly reactive DR7, DQ6 þ (100%) Thin Restricted 3þ
A2, A68, A69, B58 Highly reactive – Thick Normal 1þ
None None – Thin Normal 2þ
None None – Thin Normal 2þ
A25, A26, A33, A34, A32, A74, A23, A24, A66 None þ (58%) Thin Normal 2þ
A24, B7, B8, B81, B48, B27, B42, B54, B60, B64, B65 DR4 þ (25%) Mildly
thickened
Normal 3þ
A25, A26, B48, B60 DR7 Dr9 – Thin Normal 2þ
A25, A29, A66, B81, B56, B54, B55, B57, B7, B42,
B51, B53, B35
DR7, DR9 – Thin Normal 2þ
None DR7, DR8, DR9, DR17 – Thin Normal 2þ
None DR11, DR12, DR13,
DR14, DR17, DR8
– thin normal 2þ
Table 2. Continued
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courses were variable (Figure 2): Bioengineered valves that
elicited positive PRA titers typically did so by 4 weeks and
then returned to zero by 10 weeks, whereas cryopreserved
valves (even allogeneic) tended to evoke more persistent el-
evations. Valves maintaining superior hemodynamics typi-
cally had absent or shorter elevations of PRA.
Complement Fixing Antibody, C-Reactive Protein
Assays
C1q binding class I antibody titers were positive in 4 an-
imals receiving 4 different valve types (Table 2). Elevated
CRP titers consistently occurred only perioperatively
(P ¼ .005) (Figure E2).
Explant Pathology
Both human and baboon bioengineered valves appeared
to have virtually normal cusps qualitatively except for 1
human valve in a strongly class IIþ and C1qþ recipient
(number 10) that was described as ‘‘slightly thickened.’’
By echocardiography, this valve’s leaflets were measured
as ‘‘mildly thickened’’ (Table 2). Only 1 valve (numberThe Journal of Thoracic and Car3, cryopreserved) had discordant leaflet scoring between
echocardiography and explant observations (compare
Tables E1 and 2), although this particular valve did
exhibit gross findings of inflammatory degradation with
sinus wall thickening (Table 2). In contrast, all but 1 ref-
erence valve exhibited cusp thickening quantitatively by
echocardiography (Table E1). Frank calcifications were
not observed by radiographic examination in any of
the explanted valves. Inflammatory histologic scores dem-
onstrated some variability yet tended to correlate with
the PRA titers (Tables E1 and 2). With the exception
of a single baboon valve, all cryopreserved valves
elicited a marked inflammatory infiltrative response
(mimicking clinical experience), whereas only 2 human
bioengineered valves did. Immunohistochemical staining
confirmed the presence of B-cells in these inflammatory
infiltrates (Figure E3).
DISCUSSION
The key findings of this study include the following:
(1) Bioengineering using valve decellularization and
conditioning reduces antigenicity and prolongs normaldiovascular Surgery c Volume 145, Number 4 1103
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Sfunctional valve performance especially well for baboon
(allogeneic) but also for human (xenogeneic) sourced
valve scaffolds; (2) the intensity of immune and inflam-
matory responses is correlated with valve functional du-
rability; (3) prolonged and higher HLA titers seem to
predict accelerated functional degradation; (4) C1qþ
complement fixing antibodies were provoked by 4 differ-
ent test valves, all developed 2þ to 3þ valve regurgita-
tion; (5) technical implant surgery in baboons is
analogous to human clinical surgery; and (6) develop-
ment of HLA antibodies in baboons can be quantified
with commercially available solid-state assays used in
transplantation surgery. Our rationale for selecting the
baboon was similarity to humans in ontogeny, phylog-
eny, immunology (eg, 4 immunoglobulin-G subclasses,
complement fixation, macrophage, and T- and B-cell
functions), absence of a-Gal epitope, similar semilunar
valve microstructure, semi-upright posture, lack of sus-
ceptibility to simian herpes B virus, and robust tolerance
of cardiopulmonary bypass.18 Our data suggest that bio-
engineered cross-species human to baboon valve scaf-
fold transplants are different immunologically
(eg, provoking class IIþ antibodies) than allotransplants,
but functionally less provocative than cryopreserved
valves of either species.9
Valve Functional Performance Correlates With
Markers of Human Leukocyte Antigen Mismatch
The baboon valve diameters as measured at implant
scaled allometrically to normalized (body surface area) pe-
diatric valve annulus diameters with values similar to those
of humans (Figure 3). The EOA index increased by the
time of explant for bioengineered valves (Papio [ 29%,
human [ 19%) but decreased for cryopreserved (Papio Y
68%, human Y 57%) and porcine (Y 76%). The differ-
ences in resting pressure gradients across the clinical refer-
ence valves versus the bioengineered valves are likely
underreported because the cardiac outputs at 10 weeks
were generally higher in the animals with bioengineered
valves. There was no echocardiographic evidence of im-
pending bioengineered valve stenotic failure because trans-
valvular gradients did not increase over time, nor did
calculated valve EOAs decrease significantly at 10 or 26
weeks postimplant. The dobutamine-driven elevated car-
diac outputs only provoked physiologic flow gradients
comparable to expected values for human native valves.
In contrast, echocardiographic evidence of critical dysfunc-
tion with decreasing EOAwas manifest in all 3 types of ref-
erence valves even by 10 weeks, suggesting that the baboon
is a severe test species and robust model for such assess-
ments. Dysfunction by TEE correlated with measurements
of more intense PRA responses. Only 1 bioengineered
valve (number 10) demonstrated cuspal thickening. This
recipient had a high class IIþ response and was class1104 The Journal of Thoracic and Cardiovascular SurI C1qþ. The 2 valves that developed leaflet dysfunction
with greater than 2þ regurgitation (numbers 5 and 10)
were both associated with higher PRA titers and C1qþ an-
tibodies. To our knowledge, the correlation of the appear-
ance of C1q complement fixing antibodies and
transplanted biological valve dysfunction has not been re-
ported. Intuitively, C1qþ antibodies may be implicated in
more consequential antibody-mediated clinical tissue
transplant rejection and may thus be an observation per-
haps worthy of clinical evaluation in homograft valve
recipients exhibiting accelerated valved conduit dysfunc-
tion. Thus, various indicators of the severity of provoked
immunogenic inflammatory responses seemed to correlate
with the severity of valve dysfunction, which decellulariza-
tion and conditioning seemed to mitigate. These
observations corroborate current mechanistic theories em-
phasizing the immune and inflammatory pathogenesis of
valve degradation.20
Baboon and human HLA molecules have been compared
and are approximately 90% identical, with cross-species
differences concentrating in positions typically demonstrat-
ing polymorphisms in human alleles that serve to activate T
cells.21 Cryopreserved valves provoked strong HLA I and II
responses regardless of donor species. Of note, in the ba-
boonmodel, as in human transplantation, suspect culprit an-
tigen specificities tended to group with known shared
epitopes (eg, B8 with B64 and B65, DQ7 with DQ8, and
B7 with B42).22 The duration of the PRA elevations was
more sustained for cryo-implants, but when occurring in re-
cipients of bioengineered valves, the transient elevations
were as brief as 5 weeks duration, highlighting the need
for well-timed blood draws to identify sensitization
(Figure 2). This has significant implications for the interpre-
tations of PRA titers in older reports and assay timing in fu-
ture clinical studies.
Study Limitations
The 10-week duration of these studies was too short to
adequately assess in situ autologous in vivo recellulariza-
tion but was intentionally chosen to best capture early
immune-inflammatory responses to correlate with echo-
cardiography function and PRA titers. Only 2 recipients
with human bioengineered scaffolds were kept to 6
months; both had persistent excellent valve functionality
without MHCIþ or C1qþ antibodies, suggesting that
when antigenicity is minimized, longer-term hemody-
namic performance studies are feasible. Why antigenicity
can be variably retained at all in decellularized valves (al-
beit typically mild) is not clear from these studies. All
mammalian semilunar valves have microscopic interdigi-
tations of ventricular muscle deep within the fibrous an-
nulus where some fragmentary cell remnants could
remain despite 97% to 99% removal of DNA and other
indicators of decellularization effectiveness. Epitopesgery c April 2013
FIGURE 2. Examples of PRA time curves. A, Animal 3 received a cryo-
preserved allograft and developed both class I and II PRAs by week 3, sus-
tained through 10 weeks. B, Animal 9 received a bioengineered allograft,
did not elevate to class II, and was the only bioengineered allograft recip-
ient in which class I increased at all. Titer returned to zero by 10 weeks. C,
Animal 13 received a human bioengineered valve that provoked class II an-
tibodies at week 7 but returned to baseline by weeks 26 and 27; no class I
antibodies were detected. These serial measurements demonstrate the po-
tential difficulties in interpretation of random isolated PRA titer measure-
ments after tissue transplants. PRA, Panel-reactive antibody; Pre,
preoperatively; Post, immediately after surgery.
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with a-gal). Alternatively, mass spectrometry of detergent
decellularized equine carotid arteries has revealed small
residuals of more than 300 cell-associated proteins.23
These could include epitopes accounting for some reten-
tion of xenotransplant immunogenicity despite theThe Journal of Thoracic and Carabsence of cell fragments. Our complete cardiac experi-
ence with baboons has provided some unique observa-
tions (Table E2) that may aid other investigators
considering this species for cardiac preclinical studies.18
Cardiac surgery studies in baboons cost 500% more
than sheep. As in this study, this limits feasible animal
numbers per test group.Tissue-Engineered Valves and Preclinical Testing
With Baboons
The need for chronic animal models that are especially
relevant to humans has been identified by multiple authori-
ties as critical to ‘‘bench to bedside’’ translation of tissue-
engineering strategies.1,2,24 A principal tenet in the field
of tissue engineering is that the more a reestablished
cellular population resembles normal tissue, in cell
density, location, and phenotypes, the more likely it is
that such tissues will effectively mimic native,
particularly with the capacity for constructive and
adaptive remodeling. One pathway to a ‘‘personal’’ heart
valve would be to ‘‘tissue engineer’’ by repopulating
a decellularized allogeneic scaffold with the putative
recipient’s own cells. This could be achieved by 1 or
more strategies: (1) preimplant direct bioreactor cell
seeding (classic tissue engineering); (2) use of physical,
chemical, and biological conditioning treatments of
scaffold matrix to promote cell adhesion and in migration
in vivo as an in situ postimplantation autologous process;
and (3) introduction into the scaffold ‘‘homing’’
molecules (‘‘breadcrumbs’’ strategy) that accelerate
in vivo cell seeding.6,25 In this study, method 2 was used
without ex vivo cell seeding. However, regardless of
technique, the base scaffold must be minimally
proinflammatory or the result may be scar tissue, not
physiologic, healthy, reconstituted tissue structures.
Previous research has demonstrated that autologous cell
in migration, even without preseeding, effectively
repopulates decellularized conduit vascular walls.10 Cuspal
reendothelialization is improved with conditioning, but the
matrix of all semilunar cusps of such valve scaffolds is not
consistently (ie, all 3 cusps every time) fully repopulated
with valve interstitial cells by just autologous postsurgical
in vivo cell migration and proliferation.10,16 This is an
important distinction because repopulated cells are
needed to provide matrix remodeling protein synthesis to
establish the capacity for growth and repair, which
suggests that enhanced recellularization strategies could
be useful.14,25 Development of viable personal heart
valves using any combination of these strategies will be
strengthened by assessment methods designed to emulate
putative clinical paradigms as closely as possible. Both
clinical hemodynamic failure modes for biological
replacement valved conduits (insufficiency due to leafletdiovascular Surgery c Volume 145, Number 4 1105
FIGURE 3. Implanted valve sizes. Nomogram of BSA normalized human pediatric pulmonary valve annulus diameters derived from 14,128 normal pe-
diatric transthoracic echocardiograms archived in the Children’s Mercy Cardiac Database and on which the 14 implanted valve annulus diameters measured
by TEE at baseline after implant surgery (day 0) are graphed (green dots). Note that all but 3 were above the 50%median; the smallest valve for the recipient
size was a baboon bioengineered valve (number 8). An inadvertent ‘‘downsizing’’ bias would not explain the greater functional deterioration of the cryo-
preserved valves. Numbers identify recipient animals for each valve as identified in Table 2. PV, Pulmonary valve.
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replicated in this model. Thus, the baboon could be useful
for both mechanistic studies and as a bridge from
traditional large animals to clinical trials of tissue-
engineered cardiovascular constructs.CONCLUSIONS
The bioengineering processes used seemed to reduce the
antigenicity of semilunar valve scaffold tissues and prolong
functional performance, especially within species, but also
across genera from 2 primate families of high genomic con-
gruence. Absent or evolving postoperative major histocom-
patibility complex antibody titers were assessed and seemed
to correlate with functional measurements. This experience
suggests that the baboon model may be useful in the future
for chronic functional testing of clinical prototype human
bioengineered or even ‘‘tissue-engineered’’ replacement
valves for which human decellularized scaffolds could be
recellularized with recipient (ie, baboon) cells to closely
simulate clinical paradigms.
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FIGUREE1. Relative primate homology. Time domain is estimated with fossil or mtDNA evidence . Primates first appeared as fossils dated
to c. 95 million years ago. The depicted divergences represent generalized combinations of physical anthropological findings and computational algorithms
based on genetic sequencing data. Of the OldWorld monkeys, the baboon has the most genomic homology to humans. Data frommultiple sources, including
Raaum RL, Sterner KN, Noviello CM, Stewart C-B, Disotell TR. Catarrhine primate divergence dates estimated from complete mitochondrial genomes:
concordancewith fossil and nuclear DNA evidence. J Hum Evol. 2005;48:237-57. Adapted with permission frommaterial provided by Jeffrey Rogers, PhD,
SNPRC. Ma, Million years ago.
FIGURE E2. C-reactive protein serum titers for each animal consistently peaked 1 week postoperatively, indicating classic proinflammatory effects of
surgery and cardiopulmonary bypass. Pre, Preoperatively; Post, immediately after surgery.
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FIGURE E3. Histopathology examples of inflammatory infiltrate grades. Histologic and immunohistochemical stains of pulmonary valves. A, Histologic
section of cryopreserved human pulmonary valve explanted at 10 weeks (H&E, magnification 2.53) exemplifying a microscopic field that would rate a mild
inflammation score. Elsewhere in the specimen, areas of marked inflammation were observed; thus, the overall score for this valve explant was ‘‘marked’’
(animal number 5, Table 2). B, Immunohistochemical stain for B-cells (red, alkaline phosphatase, magnification 103) within the conduit wall inflammatory
infiltrate shown in A. C, Histologic section of cryopreserved Papio pulmonary valve explanted at 10 weeks (H&E, magnification 2.53) exemplifying a score
of ‘‘marked’’ inflammation (animal 4). D, Immunohistochemical stain for B-cells (red, alkaline phosphatase, magnification 103) within the inflammatory
infiltrate in the conduit of PRAþ recipient in C.
TABLE E1. Explant valve necropsy observations
Valve type
Animal
ID no.
Pericardial
adhesions Valve conduit wall Valve sinus wall Valve cusps
Histologic inflammatory
response score
Porcine glutaraldehyde* 1 Moderately
severe
Stiff Stiff, thick Very stiff, thick Marked
2 Severe Rigid Stiff, thick Stiff, thick Marked
Papio cryopreserved 3 Moderate Stiff, nodular suture line Nodules, scarring Thin Mild
4 Severe Scarring at suture lines Stiff, thick Thick, contracted Marked
Human cryopreserved 5 Moderately
severe
No scar No scar or calcium Thin, normal Marked
6 Moderate No scar Stiff, thick Stiff, thickened Marked
Papio 10-wk implant 7 Mild Normal Normal Thin, normal Minimal–mild
8 Mild Normal Normal Thin, normal Minimal–mild
9 Mild Normal Fibrin deposits Thin, normal Minimal–mild
Human 10-wk implant 10 Moderate Thickened Inflammatory adventitia Slightly thickened Marked
11 Mild Normal Normal Thin, normal Moderate
12 Moderate Small nodule at STJ Normal to slight thickening Thin, pliable Marked
Human 6-mo implant 13 Mild Normal Normal Thin, normal Moderate
14 Mild Normal Normal Thin, normal Minimal–mild
Porcine glutaraldehyde, Papio cryopreserved, and human cryopreserved valves are reference valves, whereasPapio 10-week, human 10-week, and human 6-month implant valves
are bioengineered valves. ID, Identification; STJ, sinotubular junction. *Porcine glutaraldehyde valve inflammatory infiltrates were limited to the adventitia only.
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TABLE E2. Observed differences between humans and baboons that may affect cardiovascular modeling
Observation Human Baboon Consequence
Liver Right sided Transverse Precludes retroflexed gastric TEE
views or subxiphoid needle
approaches.
Cardiac orientation Normal ¼ levocardia Normal ¼ levocardia Base of apex alignment and
orientation within the chest are
similar to humans and not
transversely situated as in 4-legged
food stock animals.
Right ventricle wall thickness ‘‘Normal’’ Thinner Less myocardial reserve; poorly
tolerates distention, infundibular
incisions, or acutely increased
afterloads; may be useful for
Fontan modeling.
Left ventricle muscle mass ‘‘Normal’’ Thicker with essentially concentric
hypertrophy compared with human
Diastolic stiffness. Narrow left
ventricular outflow tract; optimized
cardioplegia strategies required.
Right coronary ostia Typically smaller than left main Miniscule Smallest coronary perfusion cannulae
(1 mm) cannot cannulate.
Splanchnic venous reserve Limited Large blood volume for
autotransfusion via autonomic
reflexes
Careful weaning from
cardiopulmonary bypass with
surgeon and TEE chamber volume
monitoring to avoid acute cardiac
distention. Avoid ‘‘light’’
anesthesia. After CPB, transfuse
pump blood residual slowly.
Arterial wall thickness Large lumen to wall thickness ratio Very thick and stiff and hyper-
vasoconstrictive
Peripheral arterial cannulation
precluded; not likely a good
species for transvascular catheter
methods; enhanced fight/flight
responses; older baboons develop
hypertension and presbycardia.
Body mass Evolves with age from upper body to
lower body dominant
Upper body dominant BSA calculations should be based on
formulae that assume less
contribution from lower body mass
(eg, Haycock formula) when
normalizing measurement to BSA
(eg, indexing EOA of valves).
Demeanor Age-dependent calm Aggressive potentially bellicose All interventions under sedation/
anesthesia; perioperative
management and husbandry by
experts with proper caging,
socialization procedures,
management techniques, and so
forth are required.
Regional Primate Centers are supported by National Institutes of Health Comparative Medicine Programs (formally in the National Center for Research Resources) and tasked
with optimizing breeding, experimental modeling, availability, and medical knowledge for many Old and New World species for use in biomedical research; we found it pref-
erable to travel as a team and operate onsite at the Texas Biomedical Research Institute, where subhuman primate veterinary medicine and husbandry are optimized. However, this
adds to the additional limitation of expense. TEE, Transesophageal echocardiography; CPB, cardiopulmonary bypass; BSA, body surface area; EOA, effective orifice area.
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